NCT07195747Completed
Effects of Surgical, Percutaneous or Medical Treatments for Coronary Artery Disease on Renal Function: Long-Term Outcome. Cardiorenal-trial.
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
Background: Coronary artery disease (CAD) is treated with coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or optimized medical therapy (OMT). Their cardiovascular outcomes are well studied, but renal effects remain unclear. Objective: To evaluate long-term renal outcomes of different CAD treatment strategies. Methods: In this retrospective cohort from the MASS registry, patients with stable multivessel CAD and preserved ventricular function underwent OMT, CABG, or PCI. Annual creatinine was measured for ≥5 years, and eGFR calculated using CKD-EPI. The primary endpoint was change in renal function over time. Secondary endpoints included new-onset CKD, progression to advanced CKD, dialysis, and mortality. Analyses will use mixed-effects models and Cox regression. Results: Over 1,700 patients met inclusion criteria. Longitudinal follow-up enables robust comparison of renal trajectories across treatment groups. Conclusions: This trial highlights renal function as a primary outcome in CAD management, aiming to inform integrated strategies for patients with concurrent cardiovascular and renal risk.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1700 (actual)
- First submitted
- 19 Sept 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Nov 2025
- Lead sponsor
- Instituto do Coracao
- NCT number
- NCT07195747
What you commit to
- Study type: Observational
- Participants enrolled: 1700
- From 1 Oct 2025 to the primary completion date, 1 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of acute coronary syndrome at baseline;
- Significant left main coronary artery disease (stenosis greater than 50%);
- End-stage renal disease requiring dialysis or history of kidney transplantation.
Lab values
- Advanced chronic kidney disease (estimated glomerular filtration rate \[eGFR\] less than 30mL/min/1,73m2);
Other
- Limited life expectancy due to noncardiac comorbidities;
- Inability to maintain regular outpatient follow-up;
Who the study is looking for
- Multivessel coronary artery disease (CAD) documented by angiography (2 or more epicardial arteries with stenosis of 70% or more);
- Preserved left ventricular systolic function;
- Have undergone treatment with medical therapy (MT), coronary artery bypass graft (CABG) or percutaneous coronary artery intervention (PCI), using drug-eluting stents (DES) or bare-metal stents (BMS);
- Availability of baseline serum creatinine values at the time of enrollment;
- Availability of serum creatinine measurements for a minimum of five years.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP) Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.